T-cell co-stimulation in combination with targeting FAK drives enhanced anti-tumor immunity

被引:1
|
作者
Canel, Marta [1 ]
Taggart, David [1 ]
Sims, Andrew H. [2 ]
Lonergan, David W. [1 ]
Waizenegger, Irene C. [3 ]
Serrels, Alan [1 ]
机构
[1] Univ Edinburgh, Queens Med Res Inst, Ctr Inflammat Res, Edinburgh, Midlothian, Scotland
[2] Univ Edinburgh, Inst Genet & Mol Med, MRC, Canc Res UK,Edinburgh Ctr, Edinburgh, Midlothian, Scotland
[3] Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria
来源
ELIFE | 2020年 / 9卷
关键词
FOCAL-ADHESION KINASE; NEXT-GENERATION; PD-1; BLOCKADE; TUMOR-CELLS; TGF-BETA; CANCER; CD80; IMMUNOTHERAPY; COSTIMULATION; PROMOTES;
D O I
10.7554/elife.48092
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Focal Adhesion Kinase (FAK) inhibitors are currently undergoing clinical testing in combination with anti-PD-1 immune checkpoint inhibitors. However, which patients are most likely to benefit from FAK inhibitors, and what the optimal FAK/immunotherapy combinations are, is currently unknown. We identify that cancer cell expression of the T-cell co-stimulatory ligand CD80 sensitizes murine tumors to a FAK inhibitor and show that CD80 is expressed by human cancer cells originating from both solid epithelial cancers and some hematological malignancies in which FAK inhibitors have not been tested clinically. In the absence of CD80, we identify that targeting alternative T-cell co-stimulatory receptors, in particular OX-40 and 4-1BB in combination with FAK, can drive enhanced anti-tumor immunity and even complete regression of murine tumors. Our findings provide rationale supporting the clinical development of FAK inhibitors in combination with patient selection based on cancer cell CD80 expression, and alternatively with therapies targeting T-cell co-stimulatory pathways.
引用
收藏
页数:23
相关论文
共 50 条
  • [21] Sustained Function and Enhanced Replicative Capacity of Anti-Tumor CD4+Effectors by Enforced Co-Stimulation
    Chang, Lufen
    Jensen, Michael
    MOLECULAR THERAPY, 2006, 13 : S243 - S244
  • [22] Coenzyme A fuels T cell anti-tumor immunity
    St Paul, Michael
    Saibil, Samuel D.
    Han, SeongJun
    Israni-Winger, Kavita
    Lien, Scott C.
    Laister, Rob C.
    Sayad, Azin
    Penny, Susanne
    Amaria, Rodabe N.
    Haydu, Lauren E.
    Garcia-Batres, Carlos R.
    Kates, Meghan
    Mulder, David T.
    Robert-Tissot, Celine
    Gold, Matthew J.
    Tran, Charles W.
    Elford, Alisha R.
    Nguyen, Linh T.
    Pugh, Trevor J.
    Pinto, Devanand M.
    Wargo, Jennifer A.
    Ohashi, Pamela S.
    CELL METABOLISM, 2021, 33 (12) : 2415 - +
  • [23] Fc-silenced bispecific antibodies targeting PD-L1 and 4-1BB combine checkpoint blockade and T-cell co-stimulation to promote anti-tumor activity
    Muik, Alexander
    Altintas, Isil
    Gieseke, Friederike
    Salcedo, Theodora
    Burm, Saskia
    Diken, Mustafa
    Grunwitz, Christian
    Schuurhuis, Danita
    Kreiter, Sebastian
    Satijn, David
    Tureci, Ozlem
    Breij, Esther
    Sahin, Ugur
    Jure-Kunkel, Maria
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [24] Combination immunotherapy with oncolytic adenovirus and adoptive T-cell transfer leads to systemic anti-tumor immunity and enhanced therapeutic efficacy in a preclinical melanoma model
    Tahtinen, S.
    Gronberg-Vaha-Koskela, S.
    Lumen, D.
    Merisalo-Soikkeli, M.
    Siurala, M.
    Airaksinen, A. J.
    Vaha-Koskela, M.
    Hemminki, A.
    ANNALS OF ONCOLOGY, 2015, 26 : 11 - 12
  • [25] Leveraging T cell co-stimulation for enhanced therapeutic efficacy of trispecific antibodies targeting prostate cancer
    Sun, Yanping
    Zhou, Linling
    Gu, Xinyu
    Zhao, Jiaqi
    Bi, Jie
    Pan, Liqiang
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2025, 13 (03)
  • [26] In vitro co-stimulation of anti-tumor activity by soluble B7 molecules
    He, Wei
    Hu, Zhong-Bo
    Liu, Fang
    Feng, Xian-Qi
    Zou, Ping
    ACTA BIOCHIMICA POLONICA, 2006, 53 (04) : 807 - 813
  • [27] Targeting IL-38 triggers γδ T cell-dependent anti-tumor immunity
    da Silva, Priscila
    Mora, Javier
    Wiechmann, Svenja
    Putyrski, Mateusz
    Garcia-Pardo, Javier
    You, Xin
    Kannt, Aimo
    Ernst, Andreas
    Brune, Bernhard
    Weigert, Andreas
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2024, 54 : 349 - 349
  • [28] Targeting lL-38 triggers γδ T cell-dependent anti-tumor immunity
    Silva, Priscila
    Mora, Javier
    Ernst, Andreas
    You, Xin
    Bruene, Bernhard
    Weigert, Andreas
    JOURNAL OF IMMUNOLOGY, 2023, 210 (01):
  • [29] Antisense oligonucleotide targeting CD39 improves anti-tumor T cell immunity
    Kashyap, Abhishek S.
    Thelemann, Tamara
    Klar, Richard
    Kallert, Sandra M.
    Festag, Julia
    Buchi, Melanie
    Hinterwimmer, Lisa
    Schell, Monika
    Michel, Sven
    Jaschinski, Frank
    Zippelius, Alfred
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [30] Abatacept: a T-cell co-stimulation modulator for the treatment of rheumatoid arthritis
    Andrew J. K. Östör
    Clinical Rheumatology, 2008, 27 : 1477 - 1477